We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: A.J. Mullen10/21/2022 11:02:34 AM
1 Recommendation

Recommended By
Lance Bredvold

   of 683
Immunic (IMUX) dropped 78% today to $2.04, which takes its cap to less than cash on hand according to Yahoo. The drop is due an announcement that an interim look at a Phase 1 trial showed no separation of the treatment arm from placebo at 28 days.

It's one drug, one indication (moderate-severe psoriasis). The same drug is in Phase 1 for Prostate Cancer. Another drug is in three trials: Phase 3 for relapsing MS, Phase 2 for progressive MS and Phase 2 for another disease. Finally, they have a third drug in Phase 1 against Celiac Disease.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext